Concern that high-priced regenerative medical products could strain healthcare insurance finances
First written in FY2020-Q2. 2 of 4 entries say "Worsened", first in FY2020-Q3. Latest entry: FY2024.
The whole theme swung hardest in 2020: 29 of 64 companies on the "Worse" side.
1 other company's latest entry also says "Dropped".
- FY2024DroppedAnnual reportIn the FY2024 sections on the business environment, business and other risks, concern that high-priced regenerative medicine products will put pressure on healthcare insurance finances cannot be identified as a standalone risk.
- FY2020WorsenedAnnual report
「Kymriah, a CAR-T cell therapy marketed by Novartis Pharma, was listed for coverage under the health insurance system (priced at ¥33.49 million per treatment). In addition, Collategene, a regenerative medicine product marketed by AnGes for treating skin ulcers caused by chronic arterial occlusion, was listed for coverage in August of the same year as Japan's first gene therapy product (priced at ¥600,000 per treatment).」
In addition to high-priced CAR-T cell therapies, gene therapy products were also listed for health insurance coverage, broadening the scope of products considered in assessing the impact on healthcare insurance finances. - FY2020-Q3WorsenedAnnual report
「In the regenerative medicine and cell therapy fields, Kymriah, a CAR-T cell therapy attracting attention as a cancer immunotherapy, was listed for coverage under the health insurance system in May 2019 (priced at ¥33.49 million per treatment). In August of the same year, the regenerative medicine product Collategene, intended to treat skin ulcers caused by chronic arterial occlusion, was listed for coverage (priced at ¥600,000 per treatment) as Japan's first gene therapy product. Expectations are rising that innovative medical technologies will contribute to patient treatment and provide hope for patients with rare diseases.」
In addition to high-priced CAR-T cell therapies, the filing describes the health insurance coverage of gene therapies, broadening the scope of products considered in assessing the impact of regenerative medicine and cell therapy on healthcare insurance finances. - FY2020-Q2First statedAnnual report
「In the regenerative medicine and cell therapy fields, the CAR-T cell therapy Kymriah, which is attracting attention as a cancer immunotherapy, was listed for coverage under the health insurance system in May 2019 at a price of ¥33.49 million per treatment. With a succession of high-priced cancer therapies following Opdivo, concerns are mounting that they will put pressure on healthcare insurance finances.」
The filing describes the health insurance coverage of high-priced CAR-T cell therapies and other products, together with concerns that this will put pressure on healthcare insurance finances. It does not expressly state any direct impact on the Company in this filing.